Quoin Pharmaceuticals Ltd. (QNRX) AI Stock Summary

Snapshot

Quoin is a pre-revenue biotech developing rare-disease skin treatments, with $0 in sales and a $15.8M net loss in FY 2025. It was burning cash fast, with only 5.1 months of runway left, but a $30.8M financing announced Aug 28, 2026 is said to extend that runway into late 2029. The stock trades near its 52-week low, far below its $41.8 high.

What's Happening Right Now

• Fri 28th Aug '26 · Trial data: On Aug 28, 2026, Quoin reported positive interim Phase 2/3 data for QRX003 in Netherton Syndrome, with 4 of 6 patients hitting the primary endpoint at statistical significance and no treatment-related serious side effects.
• Fri 28th Aug '26 · Financing: On Aug 28, 2026, Quoin priced a private placement of up to $50M (about $30.8M upfront), which it says extends its cash runway into the second half of 2029.
• Fri 14th Aug '26 · Regulatory: On Aug 14, 2026, Quoin disclosed FDA conditional approval of the brand name QYLEKI for QRX003, a new patent allowance for a Netherton Syndrome combination treatment, and clearance to start a Phase 2/3 study in Peeling Skin Syndrome.
• Thu 9th Jul '26 · Regulatory: On Jul 9, 2026, the FDA cleared Quoin's IND to begin a Phase 2 study of QRX003 in Peeling Skin Syndrome, expected to start in the second half of 2026.
• Thu 18th Jun '26 · Expansion: On Jun 18, 2026, Quoin completed a Japanese subsidiary to support planned direct commercialization of QRX003 there, following Japan's orphan drug designation for the product.

Ownership

Institutions hold 64.7%, insiders hold 9.3%. In the last 90 days, four insiders including the CEO, CFO, and COO each bought shares on the open market on Aug 31, 2026, totaling $280K (about 1.9% of the company's $14.6M market cap), with no insider sales recorded.

Bottom Line

Quoin is a small, pre-revenue biotech betting everything on rare-disease drug candidates still in trials, so it has no sales and a widening net loss. What stands out is a cluster of positive events packed into late August 2026: encouraging trial data, FDA name approval for its lead drug, and a fresh $30.8M raise that the company says funds it into 2029, alongside all four top insiders buying stock the same week. The stock is still trading far below its 52-week high, reflecting how much pressure it has been under. A reader would want to weigh the encouraging trial and financing news against the fact this remains an unproven, clinical-stage company with no product revenue.